{"filing":{"accession_number":"0001193125-26-379343","cik":"0001783328","ticker":"TCRX","company_name":"TScan Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-08-27","primary_document":"d309786d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/d309786d8k.htm"},"events":[{"id":31147,"run_id":28572,"accession_number":"0001193125-26-379343","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"TScan announced a strategic reorganization involving a workforce reduction of approximately 75%, elimination of the internal manufacturing organization, and expected cumulative cost savings of $55.0 million through end of 2027, with employee-related costs of $4.1 million. The company is pausing enrollment in its Phase 3 ALLOHA-2 study and refocusing on in vivo solid tumor development to extend runway to Q4 2027.","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":33951,"accession_number":"0001193125-26-379343","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"TScan disclosed a workforce reduction of approximately 75% of its workforce in connection with a strategic reorganization, with expected employee-related costs of $4.1 million. The company is pausing enrollment in its Phase 3 ALLOHA-2 study and refocusing on in vivo solid tumor development. This is a material operational restructuring with significant exit costs that would affect a reasonable investor's assessment of the company's financial condition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33954,"accession_number":"0001193125-26-379343","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"TScan announced a strategic reorganization involving a 75% workforce reduction, pausing of its Phase 3 heme malignancies trial due to insufficient capital, and a pivot to prioritize in vivo solid tumor programs. While the disclosure includes workforce reduction (typically Item 2.05), the core event is a comprehensive strategic restructuring combining program prioritization, trial pause, and organizational streamlining. This is material to investors as it reflects capital constraints, shifts development strategy, and extends runway only to Q4 2027, but does not fit neatly into workforce_reduction alone since the strategic pivot and trial pause are equally significant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33955,"accession_number":"0001193125-26-379343","item_number":"8.01","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a strategic reorganization involving a workforce reduction of approximately 75%, elimination of the internal manufacturing organization, and cumulative cost savings of $55.0 million through end of 2027. While the disclosure also covers program pauses and strategic refocus on solid tumors, the central operational action is the workforce reduction and restructuring. The company explicitly states \"The strategic reorganization is expected to produce cumulative cost savings of $55.0 million through the end of 2027 and includes a workforce reduction of approximately 75%,\" making this a material operational restructuring event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31148,"run_id":28572,"accession_number":"0001193125-26-379343","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"TScan received written notice from Nasdaq on August 27, 2026, that its common stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), with an initial 180-day compliance period until February 23, 2027.","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":33952,"accession_number":"0001193125-26-379343","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"TScan received written notice from Nasdaq on August 27, 2026, that its common stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). The company has been provided an initial 180-day compliance period until February 23, 2027, to regain compliance. This is a classic delisting-risk disclosure under Item 3.01, as it notifies investors of the failure to satisfy a continued listing standard and the potential consequences, including possible transfer to Nasdaq Capital Market or delisting if compliance is not achieved.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31149,"run_id":28572,"accession_number":"0001193125-26-379343","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"TScan terminated the employment of Jason A. Amello (Chief Financial Officer) and Chrystal Louis, M.D., MPH (Chief Medical Officer), effective September 2, 2026, in connection with the strategic reorganization, with contractual severance entitlements.","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":33953,"accession_number":"0001193125-26-379343","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the termination of employment for two senior officers: Jason A. Amello (Chief Financial Officer) and Chrystal Louis, M.D., MPH (Chief Medical Officer), effective September 2, 2026, in connection with a strategic reorganization. While the filing also mentions Gavin MacBeath assuming CFO/principal accounting officer duties (an appointment), the primary disclosed action centers on the departure of two named executives with contractual severance entitlements. The workforce reduction of approximately 75% and strategic refocus further underscore the materiality of these executive departures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33951,"accession_number":"0001193125-26-379343","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"TScan disclosed a workforce reduction of approximately 75% of its workforce in connection with a strategic reorganization, with expected employee-related costs of $4.1 million. The company is pausing enrollment in its Phase 3 ALLOHA-2 study and refocusing on in vivo solid tumor development. This is a material operational restructuring with significant exit costs that would affect a reasonable investor's assessment of the company's financial condition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02"},{"id":33952,"accession_number":"0001193125-26-379343","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"TScan received written notice from Nasdaq on August 27, 2026, that its common stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). The company has been provided an initial 180-day compliance period until February 23, 2027, to regain compliance. This is a classic delisting-risk disclosure under Item 3.01, as it notifies investors of the failure to satisfy a continued listing standard and the potential consequences, including possible transfer to Nasdaq Capital Market or delisting if compliance is not achieved.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02"},{"id":33953,"accession_number":"0001193125-26-379343","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the termination of employment for two senior officers: Jason A. Amello (Chief Financial Officer) and Chrystal Louis, M.D., MPH (Chief Medical Officer), effective September 2, 2026, in connection with a strategic reorganization. While the filing also mentions Gavin MacBeath assuming CFO/principal accounting officer duties (an appointment), the primary disclosed action centers on the departure of two named executives with contractual severance entitlements. The workforce reduction of approximately 75% and strategic refocus further underscore the materiality of these executive departures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02"},{"id":33954,"accession_number":"0001193125-26-379343","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"TScan announced a strategic reorganization involving a 75% workforce reduction, pausing of its Phase 3 heme malignancies trial due to insufficient capital, and a pivot to prioritize in vivo solid tumor programs. While the disclosure includes workforce reduction (typically Item 2.05), the core event is a comprehensive strategic restructuring combining program prioritization, trial pause, and organizational streamlining. This is material to investors as it reflects capital constraints, shifts development strategy, and extends runway only to Q4 2027, but does not fit neatly into workforce_reduction alone since the strategic pivot and trial pause are equally significant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02"},{"id":33955,"accession_number":"0001193125-26-379343","item_number":"8.01","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a strategic reorganization involving a workforce reduction of approximately 75%, elimination of the internal manufacturing organization, and cumulative cost savings of $55.0 million through end of 2027. While the disclosure also covers program pauses and strategic refocus on solid tumors, the central operational action is the workforce reduction and restructuring. The company explicitly states \"The strategic reorganization is expected to produce cumulative cost savings of $55.0 million through the end of 2027 and includes a workforce reduction of approximately 75%,\" making this a material operational restructuring event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:23:52.629481+00:00","company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","filing_date":"2026-09-02"}]}